269 related articles for article (PubMed ID: 26334693)
1. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.
Del Prete M; Giampieri R; Loupakis F; Prochilo T; Salvatore L; Faloppi L; Bianconi M; Bittoni A; Aprile G; Zaniboni A; Falcone A; Scartozzi M; Cascinu S
Oncotarget; 2015 Oct; 6(32):33982-92. PubMed ID: 26334693
[TBL] [Abstract][Full Text] [Related]
2. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
3. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
4. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
5. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer.
Kim JH; Lee JY; Kim HK; Lee JW; Jung SG; Jung K; Kim SE; Moon W; Park MI; Park SJ
World J Gastroenterol; 2017 Jan; 23(3):505-515. PubMed ID: 28210087
[TBL] [Abstract][Full Text] [Related]
7. The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib.
Yekedüz E; Aktaş EG; Köksoy EB; Doğan N; Ürün Y; Utkan G
Future Oncol; 2022 Mar; 18(9):1067-1076. PubMed ID: 35109668
[TBL] [Abstract][Full Text] [Related]
8. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe S; Kimura K; Toyokawa T; Amano R; Tanaka H; Muguruma K; Hirakawa K
World J Gastroenterol; 2015 Sep; 21(34):9966-73. PubMed ID: 26379401
[TBL] [Abstract][Full Text] [Related]
10. Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials.
Zöhrlaut LK; Karthaus M; Vehling-Kaiser U; von Kunhardt L; Stintzing S; Heinemann V; von Einem JC
Oncol Res Treat; 2023; 46(9):348-361. PubMed ID: 37607525
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer.
Cruz-Ramos M; Del Puerto-Nevado L; Zheng B; López-Bajo R; Cebrian A; Rodríguez-Remirez M; García-García L; Solanes-Casado S; García-Foncillas J
J Geriatr Oncol; 2019 Sep; 10(5):742-748. PubMed ID: 30327283
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus.
Toh E; Wilson J; Sebag-Montefiore D; Botterill I
Colorectal Dis; 2014 Mar; 16(3):O90-7. PubMed ID: 24148256
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
14. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
15. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
[TBL] [Abstract][Full Text] [Related]
16. Poor oncologic outcomes of hepatocellular carcinoma patients with intra-abdominal infection after hepatectomy.
Ruan DY; Lin ZX; Li Y; Jiang N; Li X; Wu DH; Wang TT; Chen J; Lin Q; Wu XY
World J Gastroenterol; 2015 May; 21(18):5598-606. PubMed ID: 25987785
[TBL] [Abstract][Full Text] [Related]
17. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients.
Pistelli M; De Lisa M; Ballatore Z; Caramanti M; Pagliacci A; Battelli N; Ridolfi F; Santoni M; Maccaroni E; Bracci R; Santinelli A; Biscotti T; Berardi R; Cascinu S
BMC Cancer; 2015 Mar; 15():195. PubMed ID: 25884918
[TBL] [Abstract][Full Text] [Related]
19. A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer.
Shibutani M; Maeda K; Nagahara H; Noda E; Ohtani H; Nishiguchi Y; Hirakawa K
Anticancer Res; 2013 Aug; 33(8):3291-4. PubMed ID: 23898094
[TBL] [Abstract][Full Text] [Related]
20. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
Zaragoza J; Caille A; Beneton N; Bens G; Christiann F; Maillard H; Machet L
Br J Dermatol; 2016 Jan; 174(1):146-51. PubMed ID: 26343230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
